What is MIMs?
MIMs specializes in providing pharmaceutical companies with interactive augmented intelligence systems designed for accurate biological simulations during the early stages of drug development. Established in 2016 and headquartered in Quebec, Canada, the company empowers scientists to develop precisely targeted and personalized therapies. MIMs operates within the rapidly evolving fields of artificial intelligence and systems biology, aiming to streamline and enhance the efficiency of therapeutic innovation.
How much funding has MIMs raised?
MIMs has raised a total of $5M across 1 funding round:
Other Financing Round
$5M
Other Financing Round (2021): $5M with participation from StandUp Ventures, Real Ventures, Desjardins Capital, Anges Québec Capital, Medteq, and Anges Québec
Key Investors in MIMs
StandUp Ventures
Stand Up Ventures is a venture capital fund focused on high-growth ventures, established in 2017 and based in Toronto, Ontario, indicating a focus on early-stage companies with significant scaling potential.
Real Ventures
Real Ventures backs visionary founders building innovative tech companies with large-scale positive impacts, providing guidance and stage-specific help to entrepreneurs for global success.
Desjardins Capital
Desjardins Capital is a financial firm that likely provides strategic investment and capital to support the growth and development of companies within its portfolio.
What's next for MIMs?
The substantial enterprise-level funding MIMs has garnered suggests a strategic focus on scaling its operations and further developing its AI-driven platform. This investment is likely to accelerate the company's go-to-market strategy, expand its research and development capabilities, and solidify its position as a key player in the pharmaceutical technology sector. MIMs is poised to make significant contributions to personalized medicine and drug discovery.
See full MIMs company page
